南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

针对性地抑制膜联蛋白 A2(Annexin A2)的药理作用,可诱导 ROS 介导的细胞凋亡,并抑制肝细胞癌的发生发展。

Targeted pharmacological inhibition of Annexin A2 induces ROS-mediated apoptosis and suppresses hepatocellular carcinoma

Qian Zhang, Yehai An, Chong Qiu, Shuo Shen, Jingyang Liu, Weiyi He, Fei Xia, Ping Wang, Dandan Liu, Junhui Chen, Bin Liu, Shaohui Huang, Changgang Sun, Jigang Wang, Piao Luo

Journal:CHEMICAL ENGINEERING JOURNAL

IF:12.5

DOI:10.1016/j.cej.2026.181535

PMID:

Published:2026-09-03

research field:植物生物学分子遗传学发育生物学表观遗传学生物化学

Abstract

Oridonin (Ori) acts as a covalent inhibitor of Annexin A2 (ANXA2) to exert anticancer. • Ori irreversibly binds to the N-terminal Cys9 residue of ANXA2, mediated by its α, β-unsaturated ketone moiety. • Ori induces reactive oxygen species (ROS)-mediated apoptosis by disrupting the interaction between ANXA2 and S100A10, as well as interfering with the AKT-related signaling pathway. • ANXA2 silencing triggers ROS production and apoptosis both in vitro and in vivo; conversely, Ori did not exhibit significant anticancer effects in ANXA2-knockdown cells. • The nanomedicine, liposome-mediated targeted delivery system, is designed to enable controlled and site-specific release of Ori in tumor tissues, thereby inhibiting tumor growth and efficiently inducing ROS-mediated apoptosis. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer - related deaths worldwide. Oridonin (Ori), a diterpenoid from the traditional Chinese herb Rabdosia rubescens , shows potent broad - spectrum antitumor properties. Here, we firstly revealed Ori as a novel covalent inhibitor of Annexin A2 (ANXA2). Chemoproteomics identified that Ori irreversibly binds to the N-terminal Cys9 residue of ANXA2 via its α, β-unsaturated ketone moiety. Proteomic analysis further found that Ori induces reactive oxygen species (ROS)-mediated apoptosis through disrupting ANXA2-S100A10 interactions, while Ori-1 A without the key α, β-unsaturated ketone moiety has no such effect. ANXA2 knockdown triggers ROS production and apoptosis in vitro and in vivo. Additionally, we engineered a liposome-mediated targeted delivery system for Ori. This nanomedicine is designed to actively enable the controlled release of Ori in tumor tissues, inhibits tumor growth, and effectively induces apoptosis in a mouse xenograft model. Taken together, our findings strongly indicate that pharmacological inhibition of ANXA2 induces ROS-mediated apoptosis in HCC. The Ori-lipid nanoparticle formulation not only exhibits enhanced

本文使用的Yeasen产品

购物车
客服
转染试用